Tharimmune Appoints New Chairman and COO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Source: seekingalpha
- Executive Changes: Tharimmune announced that CEO Mark Wendland will become Chairman effective February 5, 2026, succeeding Vincent LoPriore, who has served as Chairman since May 2025 and will remain on the board, ensuring continuity and stability in governance.
- New COO Appointment: Angela Radkowski has been appointed as Chief Operating Officer, tasked with overseeing operational control functions and enterprise processes, bringing valuable management insights and efficiency improvements from her previous roles at DRW Holdings and Citadel LLC.
- Positive Market Reaction: Tharimmune's stock price rose 7.63% in pre-market trading to $4.23, reflecting investor optimism regarding the new executive appointments, which may signal future growth potential for the company.
- Strategic Implications: This executive transition not only strengthens internal management but also positions Tharimmune to enhance its competitiveness in the biotechnology sector, particularly in a rapidly evolving market landscape.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
